Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
25
HUM Quote, Financials, Valuation and Earnings
Last price:
$247.43
Seasonality move
:
2.06%
Day range:
$234.66 - $252.54
52-week range:
$213.31 - $475.00
Dividend yield:
1.43%
P/E ratio:
21.89x
P/S ratio:
0.26x
P/B ratio:
1.69x
Volume:
4.2M
Avg. volume:
1.9M
1-year change:
-45.32%
Market cap:
$29.8B
Revenue:
$106.4B
EPS (TTM):
$11.29
Analysts' Opinion
-
Consensus RatingHumana has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 17 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $287.90, Humana has an estimated upside of 16.51% from its current price of $247.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $248.00 representing 100% downside risk from its current price of $247.10.
Fair Value
-
According to the consensus of 24 analysts, Humana has 16.51% upside to fair value with a price target of $287.90 per share.
HUM vs. S&P 500
-
Over the past 5 trading days, Humana has underperformed the S&P 500 by -8.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Humana does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Humana has grown year-over-year revenues for 28 quarters straight. In the most recent quarter Humana reported revenues of $29.4B.
Earnings Growth
-
Humana earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Humana reported earnings per share of $3.98.
Enterprise value:
18.7B
EV / Invested capital:
0.61x
Price / LTM sales:
0.26x
EV / EBIT:
7.09x
EV / Revenue:
0.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
2.68%
Net Income Margin (TTM):
1.18%
Return On Equity:
8.1%
Return On Invested Capital:
4.64%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $91.5B | $102.4B | $115B | $26.4B | $29.4B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $22.05 | $24.12 | $11.29 | $6.71 | $3.98 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.9B | $19.9B | $28.3B | $32.1B | $26.3B | |
| Total Assets | $38.5B | $45.3B | $50.8B | $55.9B | $50B | |
| Current Liabilities | $14.8B | $14.8B | $19B | $20.3B | $18.5B | |
| Total Liabilities | $22.7B | $29B | $34.4B | $38.9B | $32.4B | |
| Total Equity | $15.8B | $16.3B | $16.3B | $17B | $17.6B | |
| Total Debt | $7.8B | $12.3B | $10.6B | $11.7B | $13B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.6B | $6B | -$3.6B | $1.3B | $1.9B | |
| Cash From Investing | -$96M | -$3.6B | -$3.8B | -$585M | -$1.5B | |
| Cash From Financing | -$268M | -$776M | -$2.6B | -$1.7B | -$770M | |
| Free Cash Flow | $8.4B | $5B | -$4.3B | $1B | $1.7B | |
HUM
Sector
Market Cap
$29.8B
$43.9M
Price % of 52-Week High
52.02%
45.73%
Dividend Yield
1.43%
0%
Shareholder Yield
3.96%
-0.74%
1-Year Price Total Return
-45.32%
-29.11%
Beta (5-Year)
0.532
0.772
Dividend yield:
1.43%
Annualized payout:
$3.54
Payout ratio:
31.94%
Growth streak:
7 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$255.27
200-day SMA
Sell
Level
$324.85
Bollinger Bands (100)
Sell
Level
260.15 - 341.71
Chaikin Money Flow
Buy
Level
257.5M
20-day SMA
Sell
Level
$277.12
Relative Strength Index (RSI14)
Sell
Level
36.50
ADX Line
Buy
Level
10.61
Williams %R
Neutral
Level
-75.577
50-day SMA
Sell
Level
$272.69
MACD (12, 26)
Sell
Level
-10.39
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
127.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.5641)
Buy
CA Score
(Annual)
Level (0.1639)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.3746)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Stock Forecast FAQ
In the current month, HUM has received 7 Buy ratings 17 Hold ratings, and 0 Sell ratings. The HUM average analyst price target in the past 3 months is $287.90.
-
Where Will Humana Stock Be In 1 Year?
According to analysts, the consensus estimate is that Humana share price will rise to $287.90 per share over the next 12 months.
-
What Do Analysts Say About Humana?
Analysts are divided on their view about Humana share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Humana is a Sell and believe this share price will drop from its current level to $248.00.
-
What Is Humana's Price Target?
The price target for Humana over the next 1-year time period is forecast to be $287.90 according to 24 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is HUM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Humana is a Hold. 17 of 24 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HUM?
You can purchase shares of Humana via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Humana shares.
-
What Is The Humana Share Price Today?
Humana was last trading at $247.43 per share. This represents the most recent stock quote for Humana. Yesterday, Humana closed at $247.10 per share.
-
How To Buy Humana Stock Online?
In order to purchase Humana stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 6.11% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 16.63% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 1.74% over the past day.
